Cerebraca Wafer ((Z)-n-butylidenephthalide/polymer wafer)
/ Everfront Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 20, 2024
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
(clinicaltrials.gov)
- P1/2 | N=22 | Completed | Sponsor: Everfront Biotech Co., Ltd. | Active, not recruiting ➔ Completed | N=36 ➔ 22 | Trial completion date: Dec 2024 ➔ Sep 2024
Enrollment change • Trial completion • Trial completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
January 18, 2023
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
(clinicaltrials.gov)
- P1/2 | N=36 | Active, not recruiting | Sponsor: Everfront Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Apr 2023
Enrollment closed • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1